No specific pharmacological effects mentioned

It can increase coronary artery flow and keep blood vessels unobstructed; lower cholesterol and triglycerides and promote fat decomposition; comprehensively improve microcirculation and enhance human immunity.

Significantly increase high-density lipoprotein (HDL); reduce atherosclerosis, reduce intestinal absorption of cholesterol, and prevent fat deposition in tissues.

Lower blood pressure, anti-arrhythmia; lower cholesterol and triglycerides.

It can reduce intestinal absorption of cholesterol and prevent fat deposition in tissues; it can comprehensively improve microcirculation and enhance human immunity.

Activates the pathway that inhibits the release of pain transmitters from the lateral cord, leading to the hyperactivation of intrinsic factor, which binds to the U subtype opioid receptors and inhibits 5-hydroxytryptamine and norepinephrine, thereby eliminating the pain response.

A selective α1 receptor antagonist that can inhibit the rise in blood pressure caused by α1 receptors, has a hypotensive effect on a variety of hypertensive animal models, has a long duration of hypotensive effect, does not cause reflex tachycardia during hypotensive treatment, and has no obvious first-dose effect or drug resistance after multiple oral administrations. It can reduce the total peripheral resistance of anesthetized open-chest dogs, dilate peripheral blood vessels, and has no significant effect on cardiac output. It can also relieve the sympathetic tension of the prostate and urethra caused by the excitement of the receptor through the α1 receptor blocking effect, reduce the intraurethral pressure, and improve symptoms such as urination disorders caused by benign prostatic hyperplasia.